Dr. Stephen Furlong joined AstraZeneca in 1997 where he worked for nearly 18 years in both pre-clinical drug discovery and clinical drug development. His pre-clinical work encompassed several disease areas including respiratory, inflammatory, and infectious disease, as well as neurology and psychiatry. He has also managed both global and local pre-clinical projects, including collaborative projects in psychiatric genetics with Shanghai Jiao Tong University and The University of Pennsylvania. In 2004, Dr. Furlong joined Discovery Medicine in AstraZeneca Clinical Development where he was responsible for defining biomarker technologies to support late stage Discovery and early Clinical Development projects in psychiatry. These biomarker approaches ranged from cognitive and electrophysiological measures to biochemical biomarkers for efficacy, tolerability and safety. While in Discovery Medicine, he also worked with pre-clinical and clinical project teams to help develop molecular diagnostics for infectious disease.
Beginning in 2008, Steve was Safety Science Lead in the Safety Science Section of Patient Safety where he had a global role in providing safety biomarker support to clinical project teams. In this role, he led cross-functional teams that coordinated biomarker work for drug-induced organ toxicity. He also had responsibility for overseeing collection of human biological samples used for biomarker qualification. Prior to joining AstraZeneca, Steve was on the faculty of Harvard Medical School and an Associate Immunobiologist at Brigham and Women’s Hospital. In 2015, he founded Better Biomarkers, a consulting company focused on clinical biomarker services. Steve has two nephews living with Pheo and is grateful for the opportunity to work with the PheoPara Troopers.